ANDA 212186, held by Glenmark Pharms Ltd. Amphetamine Sulfate.
As of Nov 16, 2026, ANDA 212186 (Amphetamine Sulfate), held by Glenmark Pharms Ltd, was first approved by FDA on Jan 27, 2021, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 27, 2021 | Original application | Approved | None posted |
| Amphetamine Sulfate5MG · tablet;oral | Amphetamine Sulfate | Discontinued |
| Amphetamine Sulfate10MG · tablet;oral | Amphetamine Sulfate | Discontinued |
| Feb 25, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 27, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters